See more : Singapore Exchange Limited (SPXCY) Income Statement Analysis – Financial Results
Complete financial analysis of Bio-Rad Laboratories, Inc. (BIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio-Rad Laboratories, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Novavest Real Estate AG (NREN.SW) Income Statement Analysis – Financial Results
- Sweetgreen, Inc. (SG) Income Statement Analysis – Financial Results
- Denis Chem Lab Limited (DENISCHEM.BO) Income Statement Analysis – Financial Results
- Hunting PLC (HNTIF) Income Statement Analysis – Financial Results
- SelfWealth Limited (SWF.AX) Income Statement Analysis – Financial Results
Bio-Rad Laboratories, Inc. (BIO)
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.67B | 2.80B | 2.92B | 2.55B | 2.31B | 2.29B | 2.16B | 2.07B | 2.02B | 2.18B | 2.13B | 2.07B | 2.07B | 1.93B | 1.78B | 1.76B | 1.46B | 1.27B | 1.18B | 1.09B | 1.00B | 892.72M | 817.51M | 725.88M | 549.50M | 441.90M | 426.90M | 418.80M | 396.60M | 355.30M | 328.60M | 330.30M | 310.70M | 286.70M | 236.30M | 198.90M | 159.50M | 126.60M | 102.30M |
| Cost of Revenue | 1.24B | 1.23B | 1.28B | 1.11B | 1.05B | 1.07B | 972.75M | 930.09M | 897.77M | 996.53M | 954.22M | 908.19M | 895.64M | 835.63M | 784.40M | 801.84M | 669.69M | 561.39M | 534.50M | 479.94M | 437.99M | 383.24M | 356.33M | 300.06M | 227.70M | 181.50M | 169.90M | 164.10M | 155.20M | 139.00M | 134.40M | 124.30M | 122.20M | 113.30M | 95.30M | 81.50M | 63.50M | 52.70M | 45.60M |
| Gross Profit | 1.43B | 1.57B | 1.64B | 1.44B | 1.26B | 1.22B | 1.19B | 1.14B | 1.12B | 1.18B | 1.18B | 1.16B | 1.18B | 1.09B | 999.84M | 962.52M | 791.36M | 712.54M | 646.49M | 610.07M | 565.39M | 509.49M | 461.18M | 425.83M | 321.80M | 260.40M | 257.00M | 254.70M | 241.40M | 216.30M | 194.20M | 206.00M | 188.50M | 173.40M | 141.00M | 117.40M | 96.00M | 73.90M | 56.70M |
| Gross Profit Ratio | 53.58% | 55.93% | 56.14% | 56.48% | 54.38% | 53.46% | 54.97% | 55.03% | 55.54% | 54.18% | 55.26% | 56.11% | 56.81% | 56.64% | 56.04% | 54.55% | 54.16% | 55.93% | 54.74% | 55.97% | 56.35% | 57.07% | 56.41% | 58.66% | 58.56% | 58.93% | 60.20% | 60.82% | 60.87% | 60.88% | 59.10% | 62.37% | 60.67% | 60.48% | 59.67% | 59.02% | 60.19% | 58.37% | 55.43% |
| Research & Development | 226.93M | 256.89M | 271.66M | 226.60M | 202.71M | 199.20M | 250.30M | 205.86M | 192.97M | 220.33M | 210.95M | 214.04M | 186.44M | 172.27M | 163.59M | 159.52M | 140.54M | 123.38M | 115.10M | 108.34M | 94.27M | 82.94M | 76.54M | 68.14M | 51.20M | 41.40M | 46.10M | 39.60M | 34.70M | 30.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 834.78M | 808.94M | 816.72M | 761.99M | 808.20M | 798.07M | 682.90M | 696.29M | 0.00 | 601.47M | 591.30M | 507.98M | 438.95M | 416.08M | 378.26M | 325.36M | 289.18M | 272.61M | 247.61M | 194.50M | 167.00M | 164.80M | 155.50M | 150.30M | 132.60M | 167.20M | 177.60M | 154.30M | 138.70M | 112.00M | 91.20M | 74.50M | 58.70M | 46.00M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 820.62M | 827.83M | 879.57M | 800.27M | 824.63M | 833.29M | 808.94M | 816.72M | 761.99M | 808.20M | 798.07M | 682.90M | 696.29M | 635.21M | 601.47M | 591.30M | 507.98M | 438.95M | 416.08M | 378.26M | 325.36M | 289.18M | 272.61M | 247.61M | 194.50M | 167.00M | 164.80M | 155.50M | 150.30M | 132.60M | 167.20M | 177.60M | 154.30M | 138.70M | 112.00M | 91.20M | 74.50M | 58.70M | 46.00M |
| Other Expenses | 0.00 | 44.57M | 26.78M | 24.49M | 26.09M | 36.59M | 12.20M | 14.85M | 11.08M | 13.01M | 12.77M | 21.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.31M | 27.50M | 21.00M | 19.50M | 17.90M | 16.70M | 16.80M | 16.60M | 13.90M | 12.10M | 10.30M | 7.90M | 6.40M | 5.10M | 3.30M | 2.00M |
| Operating Expenses | 1.09B | 1.08B | 1.15B | 1.03B | 1.03B | 1.03B | 1.06B | 1.02B | 954.96M | 1.03B | 1.01B | 896.94M | 882.73M | 807.48M | 765.05M | 808.34M | 648.51M | 562.33M | 531.19M | 486.61M | 419.63M | 372.11M | 349.15M | 359.06M | 273.20M | 229.40M | 230.40M | 213.00M | 201.70M | 179.60M | 183.80M | 191.50M | 166.40M | 149.00M | 119.90M | 97.60M | 79.60M | 62.00M | 48.00M |
| Cost & Expenses | 2.29B | 2.32B | 2.43B | 2.13B | 2.08B | 2.10B | 2.03B | 1.95B | 1.85B | 2.03B | 1.96B | 1.81B | 1.78B | 1.64B | 1.55B | 1.61B | 1.32B | 1.12B | 1.07B | 966.55M | 857.62M | 755.35M | 705.48M | 659.12M | 500.90M | 410.90M | 400.30M | 377.10M | 356.90M | 318.60M | 318.20M | 315.80M | 288.60M | 262.30M | 215.20M | 179.10M | 143.10M | 114.70M | 93.60M |
| Interest Income | 100.90M | 58.00M | 18.90M | 18.20M | 30.50M | 26.60M | 19.10M | 14.70M | 10.10M | 13.50M | 13.40M | 11.40M | 8.20M | 5.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 49.44M | 38.11M | 1.55M | 21.86M | 23.42M | 23.96M | 21.91M | 21.94M | 21.69M | 22.13M | 61.27M | 49.26M | 53.14M | 63.72M | 47.02M | 32.11M | 31.61M | 32.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 145.90M | 177.20M | 176.90M | 175.20M | 174.50M | 138.10M | 148.70M | 142.90M | 131.85M | 149.89M | 147.16M | 130.42M | 120.96M | 108.91M | 101.68M | 97.09M | 67.30M | 55.40M | 61.00M | 56.20M | 42.00M | 38.00M | 41.30M | 43.31M | 27.50M | 21.00M | 19.50M | 17.90M | 16.70M | 16.80M | 16.60M | 13.90M | 12.10M | 10.30M | 7.90M | 6.40M | 5.10M | 3.30M | 2.00M |
| EBITDA | -608.26M | -4.49B | 5.63B | 5.10B | 2.46B | 674.72M | 269.52M | 206.40M | 299.34M | 303.59M | 305.26M | 404.44M | 409.90M | 392.90M | 334.56M | 272.06M | 219.75M | 229.40M | 176.30M | 173.75M | 189.43M | 180.14M | 153.33M | 110.08M | 76.09M | 52.12M | 46.10M | 56.90M | 56.40M | 53.50M | 27.00M | 28.40M | 34.20M | 34.70M | 29.00M | 26.20M | 21.50M | 15.20M | 10.70M |
| EBITDA Ratio | -22.77% | 23.71% | 22.24% | 22.53% | 16.87% | 16.01% | 13.38% | 13.21% | 15.33% | 14.39% | 15.44% | 20.12% | 20.07% | 20.39% | 18.86% | 13.77% | 13.73% | 14.27% | 14.02% | 17.03% | 18.82% | 20.18% | 21.56% | 13.88% | 17.54% | 10.23% | 11.43% | 14.73% | 14.65% | 16.92% | 7.36% | 1.82% | 11.26% | 12.07% | 11.89% | 12.82% | 13.35% | 12.16% | 10.07% |
| Operating Income | 365.70M | 482.62M | 489.43M | 410.96M | 229.66M | -108.64M | 116.65M | 53.19M | 166.71M | 149.98M | 169.46M | 264.11M | 295.16M | 284.01M | 230.99M | 182.94M | 135.19M | 146.11M | 115.30M | 108.85M | 145.76M | 137.38M | 112.03M | 66.77M | 48.60M | 31.00M | 26.60M | 41.70M | 39.70M | 36.70M | 10.40M | 14.50M | 22.10M | 24.40M | 21.10M | 19.80M | 16.40M | 11.90M | 8.70M |
| Operating Income Ratio | 13.69% | 17.22% | 16.75% | 16.14% | 9.93% | -4.74% | 5.40% | 2.57% | 8.26% | 6.90% | 7.95% | 12.76% | 14.23% | 14.74% | 12.95% | 10.37% | 9.25% | 11.47% | 9.76% | 9.99% | 14.53% | 15.39% | 13.70% | 9.20% | 8.84% | 7.02% | 6.23% | 9.96% | 10.01% | 10.33% | 3.16% | 4.39% | 7.11% | 8.51% | 8.93% | 9.95% | 10.28% | 9.40% | 8.50% |
| Total Other Income/Expenses | -1.22B | -5.19B | 4.95B | 4.49B | 2.03B | 319.39M | -15.35M | -73.94M | -20.86M | -18.43M | -57.07M | -34.27M | -59.39M | -63.73M | -45.16M | -40.10M | -14.35M | -4.08M | -21.93M | -11.52M | -32.07M | -32.97M | -47.06M | -21.32M | -32.18M | 3.23M | -3.80M | -2.50M | -6.10M | -12.70M | -5.70M | 13.10M | -8.50M | -7.20M | -5.30M | -4.60M | -3.70M | -2.40M | -2.70M |
| Income Before Tax | -850.10M | -4.70B | 5.44B | 4.91B | 2.26B | 507.36M | 97.81M | 41.56M | 145.85M | 131.56M | 112.39M | 231.58M | 235.76M | 220.28M | 185.83M | 142.84M | 120.84M | 142.03M | 93.37M | 97.33M | 113.69M | 104.41M | 64.97M | 45.44M | 16.40M | 34.20M | 22.80M | 36.50M | 33.60M | 24.00M | 4.70M | 27.60M | 13.60M | 17.20M | 15.80M | 15.20M | 12.70M | 9.50M | 6.00M |
| Income Before Tax Ratio | -31.82% | -167.87% | 186.08% | 192.79% | 97.81% | 22.15% | 4.53% | 2.01% | 7.22% | 6.05% | 5.27% | 11.19% | 11.37% | 11.43% | 10.42% | 8.10% | 8.27% | 11.15% | 7.91% | 8.93% | 11.33% | 11.70% | 7.95% | 6.26% | 2.98% | 7.74% | 5.34% | 8.72% | 8.47% | 6.75% | 1.43% | 8.36% | 4.38% | 6.00% | 6.69% | 7.64% | 7.96% | 7.50% | 5.87% |
| Income Tax Expense | -212.78M | -1.08B | 1.19B | 1.10B | 502.41M | 146.36M | -16.94M | 13.44M | 32.75M | 42.71M | 34.57M | 62.28M | 57.74M | 33.35M | 36.67M | 44.58M | 26.55M | 38.76M | 15.79M | 31.04M | 37.52M | 36.54M | 20.79M | 13.63M | 4.70M | 9.90M | 6.40M | 9.10M | 8.40M | 8.40M | 1.90M | 12.00M | 5.40M | 6.50M | 5.70M | 5.70M | 5.00M | 3.40M | 1.70M |
| Net Income | -637.32M | -3.63B | 4.25B | 3.81B | 1.76B | 361.00M | 114.74M | 28.13M | 113.09M | 88.85M | 77.79M | 169.23M | 178.22M | 185.49M | 144.62M | 89.51M | 92.99M | 103.26M | 81.55M | 68.24M | 76.17M | 67.86M | 44.18M | 31.10M | 11.70M | 24.30M | 16.40M | 26.20M | 25.20M | 15.60M | 2.80M | 15.60M | 8.20M | 10.70M | 10.10M | 9.50M | 7.70M | 6.10M | 4.30M |
| Net Income Ratio | -23.86% | -129.45% | 145.57% | 149.83% | 76.08% | 15.76% | 5.31% | 1.36% | 5.60% | 4.08% | 3.65% | 8.18% | 8.60% | 9.63% | 8.11% | 5.07% | 6.36% | 8.11% | 6.91% | 6.26% | 7.59% | 7.60% | 5.40% | 4.28% | 2.13% | 5.50% | 3.84% | 6.26% | 6.35% | 4.39% | 0.85% | 4.72% | 2.64% | 3.73% | 4.27% | 4.78% | 4.83% | 4.82% | 4.20% |
| EPS | -21.82 | -121.79 | 142.61 | 127.86 | 58.93 | 12.10 | 4.12 | 0.88 | 3.74 | 3.08 | 2.72 | 5.85 | 6.39 | 6.70 | 5.28 | 3.30 | 3.48 | 3.92 | 3.13 | 2.65 | 3.00 | 2.70 | 1.79 | 1.27 | 0.49 | 0.99 | 0.67 | 1.07 | 1.03 | 0.64 | 0.12 | 0.66 | 0.35 | 0.46 | 0.45 | 0.42 | 0.34 | 0.28 | 0.22 |
| EPS Diluted | -21.82 | -121.79 | 140.83 | 126.20 | 58.27 | 11.94 | 4.07 | 0.88 | 3.71 | 3.05 | 2.69 | 5.78 | 6.29 | 6.59 | 5.20 | 3.24 | 3.41 | 3.83 | 3.06 | 2.58 | 2.90 | 2.61 | 1.74 | 1.27 | 0.48 | 0.99 | 0.66 | 1.05 | 1.03 | 0.64 | 0.12 | 0.66 | 0.35 | 0.46 | 0.45 | 0.42 | 0.34 | 0.28 | 0.22 |
| Weighted Avg Shares Out | 29.21M | 29.79M | 29.83M | 29.77M | 29.84M | 29.84M | 29.66M | 29.44M | 29.19M | 28.88M | 28.59M | 28.29M | 28.03M | 27.67M | 27.40M | 27.11M | 26.72M | 26.38M | 26.06M | 25.72M | 25.42M | 25.13M | 24.65M | 24.42M | 24.22M | 24.53M | 24.66M | 24.60M | 24.41M | 24.23M | 24.35M | 23.82M | 23.77M | 23.52M | 22.70M | 22.89M | 22.65M | 21.79M | 20.00M |
| Weighted Avg Shares Out (Dil) | 29.21M | 29.79M | 30.21M | 30.16M | 30.18M | 30.23M | 30.03M | 29.65M | 29.41M | 29.13M | 28.91M | 28.64M | 28.47M | 28.15M | 27.83M | 27.64M | 27.29M | 26.95M | 26.66M | 26.49M | 26.31M | 26.00M | 25.44M | 24.57M | 24.33M | 24.72M | 24.85M | 24.95M | 24.41M | 24.26M | 24.35M | 23.82M | 23.77M | 23.52M | 22.70M | 22.89M | 22.65M | 21.79M | 20.00M |
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down
Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.
Bio-Rad Laboratories, Inc. (BIO) Q1 2024 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Edward Chung - Head, Investor Relations Norman Schwartz - Chief Executive Officer Andy Last - Executive Vice President and COO Roop Lakkaraju...
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.29 per share, beating the Zacks Consensus Estimate of $2.04 per share. This compares to earnings of $3.34 per share a year ago.
Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip
Diagnostics firm Bio Rad Laboratories reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in China.
Bio-Rad Reports First-Quarter 2024 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2024. First-quarter 2024 total net sales were $610.8 million,...
Bio-Rad's Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Operating Officer Andy Last and Chief Financial Officer Roop K. Lakkaraju will participate in a...
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad Announces Life Science Group Management Changes
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James J. Barry, currently Senior Vice President of Global Manufacturing, to the position of Executive...
New Strong Sell Stocks for April 19th
ATNI, ABR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2023.
Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.
Source: https://incomestatements.info
Category: Stock Reports